Long-term use of approved therapy safely extends patient survival, data show
Starting Attruby (acoramidis) early and taking it continuously helps adults with transthyretin amyloid cardiomyopathy (ATTR-CM) live longer, stay out of the hospital for cardiovascular problems, and keep their heart function more stable over time.
That’s according to 4.5 years of pooled data from the now-completed Phase 3 ATTRibute-CM clinical trial (NCT03860935) and its ongoing open-label extension (OLE) study (NCT04988386). The trial had enrolled more than 600 people with the progressive heart condition.
The researchers noted that benefits from the approved oral therapy were seen in individuals with both hereditary and nonhereditary, or wild-type, forms of the disease.